The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.
Chakraborty R et al. Bone Marrow Transplant. 2016 Aug 22. doi: 10.1038/bmt.2016.214. [Epub ahead of print].

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.
Kouroukis CT et al. Curr Oncol. 2016 Aug;23(4):e409-30. doi: 10.3747/co.23.3137. Epub 2016 Aug 12.

Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.
Schmitt M et al. Vox Sang. 2016 Aug;111(2):178-86. doi: 10.1111/vox.12397.

Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.
Jacobus SJ et al. Blood Cancer J. 2016 Jul 29;6(7):e448. doi: 10.1038/bcj.2016.55.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T et al. Blood. 2016 Aug 16. pii: blood-2016-07-726729. [Epub ahead of print].

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.
Moreau P et al. Leukemia. 2016 Aug 5. doi: 10.1038/leu.2016.186. [Epub ahead of print].

Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Majer I et al. Appl Health Econ Health Policy. 2016 Aug 22. [Epub ahead of print].